blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3548011

EP3548011 - METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.04.2024
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  12.05.2023
FormerGrant of patent is intended
Status updated on  01.01.2023
FormerExamination is in progress
Status updated on  07.11.2022
FormerGrant of patent is intended
Status updated on  03.07.2022
FormerExamination is in progress
Status updated on  09.10.2020
FormerRequest for examination was made
Status updated on  06.09.2019
FormerThe international publication has been made
Status updated on  16.06.2018
Formerunknown
Status updated on  09.02.2018
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024 [2024/26]
Applicant(s)For all designated states
Regulus Therapeutics Inc.
4224 Campus Point Court, Suite 210
San Diego, CA 92121 / US
For all designated states
The Board of Regents of the University of Texas System
210 West 7th Street
Austin, TX 78701 / US
[2022/03]
Former [2019/41]For all designated states
Regulus Therapeutics Inc.
10614 Science Center Drive
San Diego, CA 92121 / US
For all designated states
The Board of Regents of the University of Texas System
210 West 7th Street
Austin, TX 78701 / US
Inventor(s)01 / ALLERSON, Charles R.
10614 Science Center Drive
San Diego, California 92121 / US
02 / PATEL, Vishal D.
210 West 7th Street
Austin, Texas 78701 / US
03 / CHAU, B. Nelson
10614 Science Center Drive
San Diego, California 92121 / US
04 / ANDROSAVICH, John R.
10614 Science Center Drive
San Diego, California 92121 / US
 [2019/41]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2023/24]
Former [2019/41]Chapman, Desmond Mark
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date17835968.304.12.2017
[2019/41]
WO2017US64432
Priority number, dateUS201662430164P05.12.2016         Original published format: US 201662430164 P
[2019/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018106568
Date:14.06.2018
Language:EN
[2018/24]
Type: A1 Application with search report 
No.:EP3548011
Date:09.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 14.06.2018 takes the place of the publication of the European patent application.
[2019/41]
Type: B1 Patent specification 
No.:EP3548011
Date:14.06.2023
Language:EN
[2023/24]
Search report(s)International search report - published on:EP14.06.2018
ClassificationIPC:A61K31/7088, A61K31/7125, A61K31/00, A61P13/12, C12N15/113
[2022/27]
CPC:
A61P13/12 (EP,KR,US); A61K31/7125 (EP,KR,US); C12N15/113 (EP,KR,US);
A61K31/436 (US); A61K31/496 (US); A61K31/517 (US);
A61K31/55 (US); A61K31/585 (US); A61K38/22 (US);
A61K38/31 (US); A61K45/06 (US); A61K9/08 (US);
C12N2310/113 (EP,KR,US); C12N2310/321 (KR); C12N2310/322 (KR);
C12N2310/3231 (EP,KR,US); C12N2310/3341 (US); C12N2310/343 (EP,KR,US);
C12N2310/346 (EP,KR,US); C12N2310/3521 (KR); C12N2310/3525 (KR);
C12N2310/3533 (KR) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP);
C12N2310/322, C12N2310/3525 (EP);
C12N2310/322, C12N2310/3533 (EP)
Former IPC [2019/41]A61K31/00, A61K31/7088, A61P13/12
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/41]
Extension statesBA03.07.2019
ME03.07.2019
Validation statesMA03.07.2019
MD03.07.2019
TN03.07.2019
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON POLYZYSTISCHER NIERENKRANKHEIT[2019/41]
English:METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE[2019/41]
French:PROCÉDÉS DE TRAITEMENT DE LA MALADIE POLYKYSTIQUE DES REINS[2019/41]
Entry into regional phase03.07.2019National basic fee paid 
03.07.2019Designation fee(s) paid 
03.07.2019Examination fee paid 
Examination procedure03.07.2019Examination requested  [2019/41]
03.07.2019Date on which the examining division has become responsible
29.01.2020Amendment by applicant (claims and/or description)
12.10.2020Despatch of a communication from the examining division (Time limit: M06)
22.04.2021Reply to a communication from the examining division
04.07.2022Communication of intention to grant the patent
04.11.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
02.01.2023Communication of intention to grant the patent
05.05.2023Fee for grant paid
05.05.2023Fee for publishing/printing paid
05.05.2023Receipt of the translation of the claim(s)
Opposition(s)15.03.2024No opposition filed within time limit [2024/21]
Fees paidRenewal fee
03.07.2019Renewal fee patent year 03
09.12.2020Renewal fee patent year 04
16.12.2021Renewal fee patent year 05
12.10.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT14.06.2023
CZ14.06.2023
DK14.06.2023
EE14.06.2023
ES14.06.2023
FI14.06.2023
HR14.06.2023
IT14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SE14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
NO14.09.2023
GR15.09.2023
IS14.10.2023
PT16.10.2023
[2024/26]
Former [2024/24]AT14.06.2023
CZ14.06.2023
DK14.06.2023
EE14.06.2023
ES14.06.2023
FI14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SE14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
NO14.09.2023
GR15.09.2023
IS14.10.2023
PT16.10.2023
Former [2024/22]AT14.06.2023
CZ14.06.2023
DK14.06.2023
EE14.06.2023
ES14.06.2023
FI14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SE14.06.2023
SK14.06.2023
SM14.06.2023
NO14.09.2023
GR15.09.2023
IS14.10.2023
PT16.10.2023
Former [2024/10]AT14.06.2023
CZ14.06.2023
EE14.06.2023
ES14.06.2023
FI14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SE14.06.2023
SK14.06.2023
SM14.06.2023
NO14.09.2023
GR15.09.2023
IS14.10.2023
PT16.10.2023
Former [2024/09]AT14.06.2023
CZ14.06.2023
ES14.06.2023
FI14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
RS14.06.2023
SE14.06.2023
SK14.06.2023
SM14.06.2023
NO14.09.2023
GR15.09.2023
IS14.10.2023
Former [2024/08]ES14.06.2023
FI14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
RS14.06.2023
SE14.06.2023
SK14.06.2023
SM14.06.2023
NO14.09.2023
GR15.09.2023
Former [2024/03]ES14.06.2023
FI14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
RS14.06.2023
SE14.06.2023
NO14.09.2023
GR15.09.2023
Former [2024/01]ES14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
NL14.06.2023
RS14.06.2023
SE14.06.2023
NO14.09.2023
GR15.09.2023
Former [2023/52]ES14.06.2023
HR14.06.2023
NL14.06.2023
RS14.06.2023
SE14.06.2023
NO14.09.2023
GR15.09.2023
Former [2023/51]ES14.06.2023
HR14.06.2023
RS14.06.2023
SE14.06.2023
NO14.09.2023
GR15.09.2023
Former [2023/50]ES14.06.2023
SE14.06.2023
NO14.09.2023
GR15.09.2023
Former [2023/48]ES14.06.2023
SE14.06.2023
NO14.09.2023
Former [2023/46]ES14.06.2023
Cited inInternational search[YA]WO2005103298  (GENACO BIOMEDICAL PRODUCTS INC [US], et al) [Y] 1-5,10-14,51-56,71-75 * sequence 24 * * table 1 * [A] 6-9,15-50,57-70;
 [I]WO2008151639  (QUERDENKER APS [DK], et al) [I] 71-75 * sequences 14, 15 * * claims 34, 35 * * the whole document *;
 [IY]WO2009109665  (SANTARIS PHARMA AS [DK], et al) [I] 71 * sequences 13, 15, 44 * * text under table 1 *[Y] 72-75;
 [YA]WO2011060100  (SANFORD BURNHAM MED RES INST [US], et al) [Y] 1-5,10-14,51-56,71-75 * sequences 11, 15 * * paragraph [0008] * * page 39 * * paragraphs [0078] - [0087] * [A] 6-9,15-50,57-70;
 [YA]WO2015123449  (UNIV JEFFERSON [US]) [Y] 1-5,10-14,51-56,71-75 * page 7 * * sequence 1 * [A] 6-9,15-50,57-70;
 [YA]  - HUAN SUN ET AL, "MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation", MOLECULAR BIOLOGY REPORTS ; AN INTERNATIONAL JOURNAL ON MOLECULAR AND CELLULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, (20091010), vol. 37, no. 6, ISSN 1573-4978, pages 2951 - 2958, XP019826622 [Y] 1-5,10-14,51-56,71-75 * page 2952 - page 2953 * * figure 2 * * figure 3 * * page 2957 * [A] 6-9,15-50,57-70
 [YA]  - V. PATEL ET AL, "miR-17?92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, US, (20130612), vol. 110, no. 26, doi:10.1073/pnas.1301693110, ISSN 0027-8424, pages 10765 - 10770, XP055320384 [Y] 1-5,10-14,51-56,71-75 * page 10765 - page 10766 * * page 10768 - page 10769 * [A] 6-9,15-50,57-70

DOI:   http://dx.doi.org/10.1073/pnas.1301693110
 [YA]  - ANDRIUS SERVA ET AL, "miR-17-5p Regulates Endocytic Trafficking through Targeting TBC1D2/Armus", PLOS ONE, (20120101), vol. 7, no. 12, doi:10.1371/journal.pone.0052555, ISSN 1932-6203, pages e52555 - e52555, XP055111293 [Y] 1-5,10-14,51-56,71-75 * page 3, paragraph 2 * [A] 6-9,15-50,57-70

DOI:   http://dx.doi.org/10.1371/journal.pone.0052555
by applicantWO2008042973
    - KURSCHAT et al., Nature Reviews Nephrology, (20140000), vol. 10, pages 687 - 699
    - PATEL et al., PNAS, (20130000), vol. 110, no. 26, pages 10765 - 10770
    - AKINC et al., Nature Biotechnology, (20080501), vol. 26, pages 561 - 569
    - NOGRADY, Medicinal Chemistry A Biochemical Approach, Oxford University Press, (19850000), pages 388 - 392
    - SHIBAZAKI et al., Human Mol. Genet., (20080000), vol. 17, no. 11, pages 1505 - 1516
    - HAPPE; PETERS, Nat Rev Nephrol., (20140000), vol. 10, no. 10, pages 587 - 601
    - ANDROSAVICH et al., Nucleic Acids Research, (20150000), vol. 44, page e13
    - ANDROSAVICH et al., Nucleic Acids Research, (20150000), vol. 44, page e 13
    - HAPPE; PETERS, Nat. Rev. Nephrol., (20140000), vol. 10, pages 587 - 601
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.